In severe chronic rhinosinusitis with polyps and asthma, dupilumab improved nasal polyp score and sense of smell vs. omalizumab at 24 wk

Key Points

• To evaluate the effectiveness of dupilumab compared to omalizumab in patients with severe chronic rhinosinusitis with polyps and asthma.
• Conducted a clinical trial involving participants with chronic rhinosinusitis and asthma.
• Administered dupilumab and omalizumab treatments.
• Assessed changes in nasal polyp score and sense of smell at 24 weeks.
• Dupilumab significantly improved nasal polyp scores compared to omalizumab.
• Patients receiving dupilumab reported a better sense of smell after 24 weeks.